Ocular Therapeutix, Inc. (OCUL)
| Market Cap | 1.60B -19.9% |
| Revenue (ttm) | 52.06M -8.1% |
| Net Income | -301.45M |
| EPS | -1.41 |
| Shares Out | 219.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,839,788 |
| Open | 6.68 |
| Previous Close | 6.72 |
| Day's Range | 6.60 - 7.34 |
| 52-Week Range | 6.00 - 16.44 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 25.45 (+249.11%) |
| Est. Earnings | Nov 10, 2026 |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of ... [Read more]
Financial Performance
In 2025, Ocular Therapeutix's revenue was $51.95 million, a decrease of -18.47% compared to the previous year's $63.72 million. Losses were -$265.94 million, 37.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OCUL stock is "Strong Buy." The 12-month stock price target is $25.45, which is an increase of 249.11% from the latest price.
News
Ocular Therapeutix management to meet with Piper Sandler
Meeting to be held in New York on October 21 hosted by Piper Sandler.
Ocular Therapeutix Transcript: Chardan's 10th Annual Healthcare Conference
SOL-1 showed superiority versus an anti-VEGF, and the Q4 2026 NDA submission remained on schedule after FDA meetings. AXPAXLI is positioned as a maintenance therapy, with SOL-1’s amended topline now expected in Q1 2028.
Ocular Therapeutix Slides: Investor presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on October 15, 2026.
Ocular Therapeutix initiated with a Buy at UBS
UBS initiated coverage of Ocular Therapeutix (OCUL) with a Buy rating and $14 price target The company’s lead asset Axpaxli is a “differentiated” long-acting retinal therapy with the potential to…
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducemen...
Ocular Therapeutix Slides: Investor presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on October 2, 2026.
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announ...
Ocular Therapeutix falls -18.2%
Ocular Therapeutix (OCUL) is down -18.2%, or -$1.76 to $7.89.
Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results
Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degenerat...
Ocular Therapeutix falls -18.1%
Ocular Therapeutix (OCUL) is down -18.1%, or -$1.75 to $7.90.
Ocular Therapeutix management to meet with Piper Sandler
Meeting to be held on September 27-October 1 hosted by Piper Sandler.
Ocular Therapeutix Transcript: 2026 Global Healthcare Conference
The session highlighted progress toward a 2027 launch for AXPAXLI, with a planned NDA submission in Q4 and strong FDA alignment. SOL-1 data showed clear superiority over EYLEA, and commercial readiness is high. Expansion into diabetic retinopathy offers significant growth potential.
Ocular Therapeutix completes pre-NDA meeting with FDA for Axpaxli
Ocular Therapeutix (OCUL) announced the completion of its pre-new drug application, or NDA, meeting with the FDA for its investigational product candidate Axpaxli for the treatment of wet age-related ...
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAX...
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today annou...
Ocular Therapeutix Slides: Investor presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on August 29, 2026.
Ocular Therapeutix Slides: Study presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on August 28, 2026.
Ocular Therapeutix Slides: Corporate presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on August 27, 2026.
Clear Street sees less competition for Ocular after EyePoint miss
Clear Street reiterates a Buy rating on Ocular Therapeutix (OCUL) (OCLX) after its competitor EyePoint (EYPT) reported the LUGANO study did not meet its primary endpoint. The trial miss potentially…
Ocular Therapeutix rises 10.4%
Ocular Therapeutix (OCUL) is up 10.4%, or $1.04 to $11.08.
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
Reports Q2 revenue $13.48M, consensus $13.2M. “We continue to execute with discipline, precision, and urgency to redefine the retina experience and make AXPAXLI available to patients as early as possi...
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular's AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026
Ocular Therapeutix Earnings release: Q2 2026
Ocular Therapeutix released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Ocular Therapeutix Quarterly report: Q2 2026
Ocular Therapeutix has published its Q2 2026 quarterly earnings report on August 3, 2026.
Ocular Therapeutix Slides: Study Result presentation
Ocular Therapeutix has posted slides in relation to its latest quarterly earnings report, which was published on August 2, 2026.